Current data from real-world settings indicate treatment initiation with lenalidomide and disease monitoring in patients with myelodysplastic syndrome with del(5q) (MDS-del[5q]) greatly vary, ...

Deletions of the long (q) arm of chromosome 5 [del(5q)]occur in patients with myelodysplastic syndromes (MDS) including, but not limited to, those who meet the WHO definition of the 5q− syndrome.

Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However, ...

Myelodysplastic syndromes (MDS) remain challenging to both clinicians and biologists. This year's edition of the Annual Meeting of the American Society of Hematology has provided several breakthroughs ...

Revlimid is showing promise for patients with low-risk MDS, according to the results of a recent study. Nearly 40 percent of patients with low intermediate-1 risk myelodysplastic syndrome (MDS) who ...

Celgene Corporation (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) granted approval of REVLIMID (lenalidomide) which is indicated for the treatment of patients with ...

Celgene International Sàrl (NASDAQ: CELG) announced that, following discussions with the European Medicines Agency (EMEA) and the EMEA’s Committee for Medicinal Products for Human use (CHMP), it has ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...